Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.69 |
| ▸ | KIT | P10721 | 5/20 | 0.53 |
| ▸ | FLT3 | P36888 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5889195 | 0.90 | KDR (0.72) | KDRKIT | |
| SCHEMBL5889024 | 0.88 | KDR (0.54) | KDRKITFLT3 | |
| SCHEMBL5889049 | 0.88 | KDR (0.73) | KDRKIT | |
| SCHEMBL5889238 | 0.87 | KDR (0.68) | KDRKIT | |
| SCHEMBL5889040 | 0.87 | KIT (0.54) | KDRKITFLT3 | |
| SCHEMBL5889028 | 0.87 | KDR (0.71) | KDRKIT | |
| SCHEMBL5889071 | 0.86 | KDR (0.63) | KDRKIT | |
| SCHEMBL6803356 | 0.86 | KDR (0.74) | KDRKIT | |
| SCHEMBL5889252 | 0.85 | KDR (0.67) | KDRKIT | |
| SCHEMBL5889162 | 0.85 | KDR (0.67) | KDRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115597-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-10-03 | — | — | US | claimed |
| US-20040063720-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-04-01 | — | — | US | claimed |
| US-20040023977-A1 | Process for making substituted thiazolyl-amino pyrimidinyl | LARSEN ROBERT D (US) | 2004-02-05 | — | — | US | claimed |
| EP-1341540-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2003-09-10 | — | — | EP | claimed |
| US-20020137755-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2002-09-26 | — | — | US | claimed |
| WO-2002045652-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2002-06-13 | — | — | WO | claimed |
| US-7115597-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040063720-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-04-01 | — | — | US | disclosed |
| US-20040023977-A1 | Process for making substituted thiazolyl-amino pyrimidinyl | LARSEN ROBERT D (US) | 2004-02-05 | — | — | US | disclosed |
| EP-1341540-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20020137755-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2002-09-26 | — | — | US | disclosed |
| WO-2002045652-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023977-A1 | Process for making substituted thiazolyl-amino pyrimidinyl | TYK2, ERBB2, JAK2 | KDR 72/4885KIT 367/4885FLT3 12/4885 |
| US-20020137755-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885KIT 957/4885FLT3 63/4885 |
| US-20040063720-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885KIT 957/4885FLT3 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.